## Edgar Filing: Javitt Jonathan C - Form 4

Form 4											
August 28,	ЛД								OMB AF	PROVAL	
	UNITED	STATES S			AND EXCH , D.C. 2054		GE CO	OMMISSION	OMB Number:	3235-0287	
Check t if no lot subject Section Form 4 Form 5 obligati may con <i>See</i> Inst 1(b).	nger to 16. or Filed pur ons ntinue.	<b>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								January 31, 2005 average urs per 0.5	
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Javitt Jonathan C			2. Issuer Name and Ticker or Trading Symbol BRAINSTORM CELL THERAPEUTICS INC [BCLI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	NSTORM CELL EUTICS INC., 110	(] 0		f Earliest T Day/Year) 008	ransaction		_	_X Director Officer (give t elow)		Owner er (specify	
				mendment, Date Original Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul>			
(City)	(State)	(Zip)	Tabl	le I - Non-l	Derivative Sec	uritie		red, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		Fransaction Date 2A. Deemed onth/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired (A Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Prio				Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	08/27/2008			X	1,000,000	A	\$ 0.01	960,000	D		
Common Stock	08/27/2008			S	40,000 <u>(1)</u>	D	\$ 0 25	960,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Javitt Jonathan C - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	ofDeriv Secu Acqu Disp	umber of vative rities hired (A) or osed of (D) r. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Warrant to Purchase Common Stock	\$ 0.01	08/27/2008		Х		1,000,000	09/06/2007	11/04/2010	Common Stock	1,00

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
FB	Director	10% Owner	Officer	Other		
Javitt Jonathan C C/O BRAINSTORM CELL THERAPEUTICS INC. 110 EAST 59TH STREET NEW YORK, NY 10022	Х					
Signatures						
/s/ Thomas B. Rosedale (Pursuant to Power of Attorney)	08/28/2008					
**Signature of Reporting Person		Date				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Sale of derivative securities as payment of exercise price incident to the exercise of a derivative security.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.